Recent patents of dipeptidyl peptidase IV inhibitors

Bibliography

• Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24
   PubMed Web of Science ®Google Scholar
• Rasmussen HB, Branner S, Wiberg FC, Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25
   PubMedGoogle Scholar
• Lambeir AM, Durinx C, Scharpe S, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94
   PubMed Web of Science ®Google Scholar
• Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001;54:249-64
   PubMed Web of Science ®Google Scholar
• Vivier I, Marguet D, Naquet P, Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol 1991;147:447-54
   PubMedGoogle Scholar
• Yu DM, Slaitini L, Gysbers V, Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol 2011;73:102-11
   PubMed Web of Science ®Google Scholar
• Rogge L, Bianchi E, Biffi M, Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet 2000;25:96-101
   PubMedGoogle Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
   PubMed Web of Science ®Google Scholar
• Holst JJ, Christensen M, Lund A, Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011;13(Suppl 1):89-94
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911-16
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Shintani N, Hayata A, Trophic effects of PACAP on pancreatic islets: a mini-review. J Mol Neurosci 2011;43:3-7
   Google Scholar
• Chu JY, Cheng CY, Lee VH, Secretin and body fluid homeostasis. Kidney Int 2011;79:280-7
   Google Scholar
• Oravecz T, Pall M, Roderiquez G, Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865-72
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600-7
   PubMed Web of Science ®Google Scholar
• Kos K, Baker AR, Jernas M, DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009;11:285-92
   PubMed Web of Science ®Google Scholar
• Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann NY Acad Sci 2003;994:162-8
   PubMed Web of Science ®Google Scholar
• O'Connor TM, O'Connell J, O'Brien DI, The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167-80
   PubMed Web of Science ®Google Scholar
• Busso N, Wagtmann N, Herlling C, Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005;166:433-42
   PubMedGoogle Scholar
• Marguet D, Baggio L, Kobayashi T, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335-43
   PubMed Web of Science ®Google Scholar
• Barreto SG, Carati CJ, Toouli J, The islet-acinar axis of the pancreas: more than just insulin. Am J Physiol Gastrointest Liver Physiol 2010;299:G10-22
   PubMedGoogle Scholar
• Karin N. The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J Leukoc Biol 2010;88:463-73
   PubMedGoogle Scholar
• Yu DM, Yao TW, Chowdhury S, The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010;277:1126-44
   PubMed Web of Science ®Google Scholar
• Martin M, Huguet J, Centelles JJ, Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J Immunol 1995;155:4630-43
   PubMedGoogle Scholar
• UniProt Consortium. Ongoing and future developments at the universal protein resource. Nucleic Acids Res 2011;39:D214-19
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Raj BK, Calvo B, Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA 1994;91:5657-61
   PubMed Web of Science ®Google Scholar
• Lee KN, Jackson KW, Christiansen VJ, A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004;103:3783-8
   PubMed Web of Science ®Google Scholar
• Abbott CA, McCaughan GW, Levy MT, Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain. Eur J Biochem 1999;266:798-810
   PubMedGoogle Scholar
• Ishii T, Ohnuma K, Murakami A, CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001;98:12138-43
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Uchiyama M, Yamochi T, Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007;282:10117-31
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Yamochi T, Uchiyama M, CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 2004;101:14186-91
   PubMedGoogle Scholar
• Cheng HC, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003;278:24600-7
   PubMedGoogle Scholar
• Gonzalez-Gronow M, Grenett HE, Weber MR, Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J 2001;355:397-407
   PubMedGoogle Scholar
• Girardi AC, Degray BC, Nagy T, Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001;276:46671-7
   PubMed Web of Science ®Google Scholar
• Davoodi J, Kelly J, Gendron NH, The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics 2007;7:2300-10
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Shaw S. Lymphocyte interactions with extracellular matrix. FASEB J 1991;5:2292-9
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
   PubMedGoogle Scholar
• Ahren B, Simonsson E, Larsson H, Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002;25:869-75
   PubMed Web of Science ®Google Scholar
• Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-40
   PubMed Web of Science ®Google Scholar
• Davidson JA. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010;85:S27-37
   PubMedGoogle Scholar
• Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs 2011;20:723-32
   PubMed Web of Science ®Google Scholar
• Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 2004;19:1345-51
   PubMed Web of Science ®Google Scholar
• Sedo A, Duke-Cohan JS, Balaziova E, Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005;7:253-69
   PubMed Web of Science ®Google Scholar
• Ospelt C, Mertens JC, Jungel A, Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010;62:1224-35
   PubMedGoogle Scholar
• Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010;88:125-31
   PubMed Web of Science ®Google Scholar
• Umezawa H, Aoyagi T, Ogawa K, Diprotins A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria. J Antibiot (Tokyo) 1984;37:422-5
   PubMed Web of Science ®Google Scholar
• Demuth HU, Baumgrass R, Schaper C, Dipeptidylpeptidase IV–inactivation with N-peptidyl-O-aroyl hydroxylamines. J Enzyme Inhib 1988;2:129-42
   PubMedGoogle Scholar
• Flentke GR, Munoz E, Huber BT, Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 1991;88:1556-9
   PubMed Web of Science ®Google Scholar
• Li J, Wilk E, Wilk S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch Biochem Biophys 1995;323:148-54
   PubMed Web of Science ®Google Scholar
• Augustyns K, Van der Veken P, Senten K, The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem 2005;12:971-98
   PubMed Web of Science ®Google Scholar
• Boduszek B, Oleksyszyn J, Kam CM, Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J Med Chem 1994;37:3969-76
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S. WO0202560A2; 2002
   Google Scholar
• Boehringer Ingelheim Pharma KG. WO02068420A1; 2002
   Google Scholar
• Merck & Co. US6699871B2; 2004
   Google Scholar
• F. Hoffmann-La Roche AG. US6166063; 2000
   Google Scholar
• Bristol-Myers Squibb Co. US6395767B2;2002
   Google Scholar
• Takeda. WO2005095381A1; 2005
   Google Scholar
• Mentlein R. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best Pract Res Clin Endocrinol Metab 2009;23:443-52
   Google Scholar
• Danilova O, Li B, Szardenings AK, Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg Med Chem Lett 2007;17:507-10
   Google Scholar
• Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 2005;8:51-8
   PubMed Web of Science ®Google Scholar
• Kirby M, Yu DM, O'Connor S, Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2010;118:31-41
   Web of Science ®Google Scholar
• Lopez A, Tarrago T, Giralt E. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010. Expert Opin Ther Patent 2011;21:1023-44
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. WO2007053819A2; 2007
   Google Scholar
• National Health Research Institutes (Taiwan). US20070082932A1; 2007
   Google Scholar
• National Health Research Institutes (Taiwan). WO2009111239A2; 2009
   Google Scholar
• Tufts University. WO2008119005A1; 2008
   Google Scholar
• Kainos Medicine, ICC. WO2008087560A2; 2008
   Google Scholar
• Alantos Pharmaceuticals, I. WO2006116157A2; 2006
   Google Scholar
• Merck & Co., I. WO2006009886A1; 2006
   Google Scholar
• Merck & Co., I. WO2006127530A2; 2006
   Google Scholar
• Novartis. WO2008077597A1; 2008
   Google Scholar
• F. Hoffmann-La Roche AG. WO2006066770; 2006
   Google Scholar
• Merck & Co., I. WO2006039325A2; 2006
   Google Scholar
• F. Hoffmann-La Roche AG. WO2006066747A1; 2006
   Google Scholar
• Cox JM, Harper B, Mastracchio A, Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007;17:4579-83
   PubMed Web of Science ®Google Scholar
• Astellas Pharma. WO2006098342A1; 2006
   Google Scholar
• Dong-A Pharm. D.-A. WO2008130151A1; 2008
   Google Scholar
• Dong-A Pharm. US20100120790A1; 2010
   Google Scholar
• Eli Lilly and Co. WO2007015767A1; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO2006071762A2; 2006
   Google Scholar
• Phenomix Corp. WO2006017292A1; 2006
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. WO2008089636A1; 2008
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co. EP2133077A1; 2007
   Google Scholar
• Bristol-Myers Squibb Co. WO2006127287A2; 2006
   Google Scholar
• Bristol-Myers Squibb Co. WO2006071752A1; 2006
   Google Scholar
• Merck & Co., I. WO2006078676A2; 2006
   Google Scholar
• Boehringer Ingelheim Pharma KG. WO2008017670A1; 2008
   Google Scholar
• Concert Pharmaceuticals. WO2008141021A1; 2008
   Google Scholar
• Aurigene Discovery Technologies. WO2006134613A2; 2006
   Google Scholar
• Peakdale Molecular. WO2008040974A1; 2008
   Google Scholar
• Peakdale Molecular. WO2008040995A1; 2008
   Google Scholar
• Sanofi-Aventis. WO2006111261A1; 2006
   Google Scholar
• Dainippon Sumitomo Pharma. EP1690863A1; 2006
   Google Scholar
• Dainippon Sumitomo Pharma. US20070105890A1; 2007
   Google Scholar
• Sanofi-Aventis. WO2006015691A1; 2006
   Google Scholar
• Sanofi-Aventis. WO2006015699A1; 2006
   Google Scholar
• Sanofi-Aventis. WO2006015701A1; 2006
   Google Scholar
• Sanofi-Aventis. WO2006015700A1; 2006
   Google Scholar
• Boehringer Ingelheim Pharma KG. WO2006027204A1; 2006
   Google Scholar
• Boehringer Ingelheim Pharma KG. WO2006029769; 2006
   Google Scholar
• Boehringer Ingelheim Pharma KG. WO2009147125A1; 2009
   Google Scholar
• Boehringer Ingelheim Pharma KG. WO2010086411A1; 2010
   Google Scholar
• Boehringer Ingelheim Pharma KG. US20100173916A1; 2010
   Google Scholar
• Boehringer Ingelheim Pharma KG. US20100204250A1; 2010
   Google Scholar
• Novartis. WO2007071738A1; 2007
   Google Scholar
• Takeda. WO2006020017A2; 2006
   Google Scholar
• Takeda. WO2007112347; 2007
   Google Scholar
• Takeda. US7732446B1; 2010
   Google Scholar
• Bristol-Myers Squibb Co. WO2008064107; 2008
   Google Scholar
• LG Life Sciences. WO2009082134A2; 2009
   Google Scholar
• F. Hoffmann-La Roche AG. WO2006058628A2; 2006
   Google Scholar
• Lubbers T, Bohringer M, Gobbi L, 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007;17:2966-70
   Google Scholar
• Boehringer M, Fischer H, Hennig M, Aryl- and heteroaryl-substituted aminobenzo[a]quinolizines as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2010;20:1106-8
   PubMed Web of Science ®Google Scholar
• Merck & Co., I. WO2006058064; 2006
   Google Scholar
• Merck & Co., I. WO2007024993; 2007
   Google Scholar
• Edmondson SD, Mastracchio A, Cos JM, Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg Med Chem Lett 2009;19:4097-101
   Google Scholar
• Merck. WO2006023750A2; 2006
   Google Scholar
• Santhera Pharmaceuticals. WO2006097175A1; 2006
   Google Scholar
• Santhera Pharmaceuticals. WO2008028662A1; 2008
   Google Scholar
• LG Life Sciences. WO2006104356A1; 2006
   Google Scholar
• LG Life Sciences. WO2008093960A1; 2008
   Google Scholar
• Eli Lilly and Co. WO2007015805; 2007
   Google Scholar
• Eli Lilly and Co. WO2007015807; 2007
   Google Scholar
• Panacea Biotec. WO2009093269; 2009
   Google Scholar
• Takeda. WO2006068978A2; 2006
   Google Scholar
• Glenmark Pharmaceuticals. WO20060400625A1; 2006
   Google Scholar
• Glenmark Pharmaceuticals. WO2006011035A1; 2006
   Google Scholar
• Glenmark Pharmaceuticals. WO2007099385A1; 2007
   Google Scholar
• Santhera Pharmaceuticals. WO2006013104; 2006
   Google Scholar
• Santhera Pharmaceuticals. WO2009003681; 2009
   Google Scholar
• Orchid Research Laboratories. WO2008029217; 2008
   Google Scholar
• Orchid Research Laboratories. WO2010079413; 2010
   Google Scholar
• Ranbaxy Laboratories. WO07029086; 2007
   Google Scholar
• Sattigeri JA, Andappan MM, Kishore K, Discovery of conformationally rigid 3-azabicyclo[3.1.0]hexane-derived dipeptidyl peptidase-IV inhibitors. Bioorg Med Chem Lett 2008;18:4087-91
   Google Scholar
• Singh S, Sethi S, Khanna V, RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. Eur J Pharmacol 2011;652:157-63
   Google Scholar
• Concert Pharmaceuticals. WO2009045476; 2009
   Google Scholar
• Glenmark Pharmaceuticals. WO2006090244; 2006
   Google Scholar
• Matrix Laboratories. WO2007113634; 2007
   Google Scholar
• Novartis. WO2009068531; 2009
   Google Scholar
• Lupin. WO2009037719; 2009
   Google Scholar
• Lupin. WO2010146597; 2010
   Google Scholar
• Susan Marie Royalty. WO2006012441; 2006
   Google Scholar
• Susan Marie Royalty. WO2006012395; 2006
   Google Scholar
• Susan Marie Royalty. US7842707; 2010
   Google Scholar
• Phenomix Corp. US20060264401; 2006
   Google Scholar
• Phenomix Corp. US20070185061; 2007
   Google Scholar
• Phenomix Corp. US7317109; 2008
   Google Scholar
• Phenomix Corp. US20070299036; 2007
   Google Scholar
• Phenomix Corp. US20080182995; 2008
   Google Scholar
• Phenomix Corp. WO2008027273; 2008
   Google Scholar
• Phenomix Corp. WO2008144730; 2008
   Google Scholar
• Phenomix Corp. WO2010107809; 2010
   Google Scholar
• Phenomix Corp. US7674913; 2010
   Google Scholar
• Phenomix Corp. US7576121; 2009
   Google Scholar
• Phenomix Corp. US20080300413; 2008
   Google Scholar
• Tufts University. WO2007100374; 2007
   Google Scholar
• Tufts University. WO2008118848; 2008
   Google Scholar
• Tufts University. WO2010099537; 2010
   Google Scholar
• Connolly BA, Sanford DG, Chiluwal AK, Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem 2008;51:6005-13
   Google Scholar
• F. Hoffmann-La Roche AG. WO2007054577; 2007
   Google Scholar
• Cadila Pharmaceuticals. WO2010029422; 2010
   Google Scholar
• Kuhn-Wache K, Bar JW, Hoffmann T, Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site. Biol Chem 2011;392:223-31
   Google Scholar
• Ansorge S, Nordhoff K, Bank U, Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem 2011;392:153-68
   Google Scholar
• Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 2011;34(Suppl 2):S276-8
   PubMed Web of Science ®Google Scholar